Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Xueliang Fu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2454-207X; OpenAlex author ID A5101662772. Sources: OpenAlex.

Their work

Papers
25 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2015: 2 papers · 2016: 4 papers · 2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 25

  1. Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.28909↗
  2. L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation Co-author DOI 10.64898/2026.03.06.710237↗
  3. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-024-07110-w↗
  4. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1007/s10495-023-01843-3↗
  5. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  6. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  7. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  8. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. Co-author DOI 10.1002/1878-0261.12970↗
  9. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.016↗
  10. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  11. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  12. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. First author DOI 10.3892/ol.2020.11866↗
  13. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. Co-author DOI 10.1038/s41419-019-2072-5↗
  14. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/8656282↗
  15. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma. Co-author PMID 30906634↗
  16. High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-018-34094-3↗
  17. Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients. Co-author DOI 10.3892/ol.2018.8452↗
  18. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384101.2017.1356510↗
  19. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. Co-author DOI 10.7150/jca.20086↗
  20. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep33535↗
  21. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review. First author DOI 10.1097/md.0000000000003009↗
  22. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.6772↗
  23. Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma. First author PMID 27648368↗
  24. High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-015-0202-1↗
  25. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.5939↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minwei Yang · 23 shared papers, 2015–2026 · strength 2.42
  2. Jian‐Yu Yang · 22 shared papers, 2015–2026 · strength 2.21
  3. Yan‐Miao Huo · 21 shared papers, 2015–2024 · strength 1.94
  4. Yongwei Sun · 21 shared papers, 2015–2024 · strength 1.83
  5. Rong Hua · 19 shared papers, 2015–2024 · strength 1.65
  6. Dejun Liu · 15 shared papers, 2015–2024 · strength 1.41
  7. Shu‐Heng Jiang · 7 shared papers, 2016–2026 · strength 0.94
  8. Junfeng Zhang · 10 shared papers, 2016–2023 · strength 0.89
  9. Ruizhe He · 8 shared papers, 2018–2023 · strength 0.84
  10. Jia-Hao Zheng · 5 shared papers, 2022–2026 · strength 0.83
  11. Wei Chiang Liu · 7 shared papers, 2016–2022 · strength 0.66
  12. Zhigang Zhang · 6 shared papers, 2016–2026 · strength 0.60
  13. Hong‐Fei Yao · 4 shared papers, 2022–2024 · strength 0.59
  14. Junfeng Zhang · 6 shared papers, 2015–2021 · strength 0.49
  15. Yong-Wei Sun · 2 shared papers, 2026 · strength 0.46
  16. Jian Yang · 3 shared papers, 2022–2023 · strength 0.40
  17. Qin-Yuan Jia · 2 shared papers, 2023–2024 · strength 0.33
  18. Ping Lu · 3 shared papers, 2020–2022 · strength 0.32
  19. Jing Xue · 3 shared papers, 2020–2022 · strength 0.31
  20. Yongsheng Jiang · 3 shared papers, 2019–2022 · strength 0.28
  21. Dejun Liu · 4 shared papers, 2016–2019 · strength 0.25
  22. Dapeng Xu · 2 shared papers, 2022 · strength 0.25
  23. Yongsheng Jiang · 3 shared papers, 2018–2019 · strength 0.25
  24. Wei Liu · 2 shared papers, 2021–2022 · strength 0.24
  25. Pei‐Xuan Ji · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.